AA
MRKR icon

ALPS Advisors’s Marker Therapeutics MRKR Stock Holding History

ALPS Advisors’s Portfolio MRKR Stock Details MRKR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,183
Closed -$172K – 943
2021
Q3 		$172K Sell
10,183
-751
-7% -$15.4K ﹤0.01% 903
2021
Q2 		$305K Buy
+10,934
New +$288K ﹤0.01% 823
2019
Q4 		– Sell
-9,106
Closed -$465K – 844
2019
Q3 		$465K Sell
9,106
-409
-4% -$24.2K ﹤0.01% 505
2019
Q2 		$754K Buy
+9,515
New +$565K 0.01% 400

Other funds holding MRKR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ALPS Advisors's MRKR Position: Q4 2021 in Review

ALPS Advisors sold out of Marker Therapeutics (MRKR) in Q4 2021, closing a stake of 10,183 shares — an estimated $172K sold.

ALPS Advisors first reported a position in MRKR in Q2 2019 and held it in 4 quarters. The position peaked at $754K in Q2 2019. 64 funds tracked by Wall St. Rank hold MRKR as of Q4 2021.

  • ALPS Advisors reported no remaining Marker Therapeutics position as of Q4 2021 after selling out during the quarter.
  • ALPS Advisors sold 10,183 Marker Therapeutics shares in Q4 2021, an estimated $172K.
  • ALPS Advisors first reported a position in Marker Therapeutics in Q2 2019 and held it in 4 quarters.
  • ALPS Advisors's Marker Therapeutics position peaked at $754K in Q2 2019.
  • 64 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2021.

Based on ALPS Advisors's 13F filing for Q4 2021, filed 9 Feb 2022.